Abbott (NYSE:ABT) recently announced that new real-world data shows that users of its FreeStyle Libre continuous glucose monitor (CGM) have improved on four different fronts.
Users of the Abbott Park, Ill.–based company’s device showed better glucose control, increased time in target glucose range, decreased time in hyperglycemia and hypoglycemia and reduced HbA1C (average glucose levels over a three-month period).
“As the world leader in sensor-based glucose monitoring with more than 2 million users, Abbott’s FreeStyle Libre system has an unmatched body of real-world evidence supporting its clinical benefits,” Abbott divisional VP of global medical & scientific affairs & CMO of diabetes care Dr. Mahmood Kazemi said in a news release yesterday.
“Time and time again, we’ve seen meaningful data that reaffirm our technology’s direct impact in achieving better health outcomes for people with diabetes,” Kazemi said.
Abbott presented the newfound data abstracts at the Advanced Technologies & Treatments for Diabetes (ATTD) in Madrid. The company shared that people with Type 1 diabetes using the FreeStyle Libre system with a baseline HbA1C above 7.5% showed an average reduction of 1.4%, while users with Type 2 diabetes reduced by 1.2% on average.
Analysis of real-world data showed that a higher frequency of scanning is associated with increased time in the target glucose range for people with diabetes, according to Abbott. FreeStyle Libre users with the lowest scanning frequency (3.3 scans per day) spent 54.6% of the time in the target range, while the highest scanners (29.3 per day) spent 66.7% of the time in the desired range.
Abbott said its FreeStyle Libre system is currently used by more than 2 million people across 46 countries and has partial or full reimbursement in 36 countries, including the U.S., United Kingdom, France, Ireland and Japan.
